COGNITE
5.10.2021 13:02:10 CEST | Business Wire | Press release
In the midst of the largest industrial revolution, Cognite , a leader in industrial digitalization, announced the release of The Definitive Guide To Industrial DataOps . A first for the industry, the book defines and explains the emerging discipline of Industrial DataOps in language crafted for both business and IT professionals, while addressing the urgency driven by accelerating, data-driven shifts that modern organizations now navigate. The insights and industry expertise captured in the book also offer organizations practical advice on successful Industrial DataOps adoption and scaling. A request for proposal (RFP) guide, and a self-assessment to evaluate organizational readiness and map out challenges, round out the actionable insights and tools covered in the book.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005582/en/
Industrial DataOps is already becoming a driving force in industrial transformations, helping accelerate digital maturity, enabling data teams to deliver more digital products, and realizing more operational value at scale. In a 2020 survey of global companies, McKinsey found organizations that embedded DataOps could see the volume of new features increase by 50 percent because data automation enables quicker development iterations.
“Data trust comes from connecting the dots between desired outcomes and relevant use-case-oriented data products,” says Forrester VP, Principal Analyst Michele Goetz. “An Industrial DataOps platform brings context to data conditions and ensures business impacting data anomalies are caught early to mitigate costly issues. A DataOps platform also ensures data complies with data models and output standards to drive results from event-based intelligence inside processes.”
‘The Definitive Guide to Industrial DataOps’ was written to de-hype industrial digitalization and to help make sense of how Industrial DataOps allows organizations to manage complex data. The book’s structure reflects the journey that industrial companies will take as they evaluate, adopt, and scale Industrial DataOps across their organizations. The early chapters cover the urgency of Industrial DataOps and get readers to take stock of their industrial organizations’ digital maturity. The core chapters address the discipline itself, its key principles, and how to best extract value from data, while the final chapters define the way forward: scaling Industrial DataOps and putting it into practice.
“Industrial DataOps is a crucial and necessary tool to make digital transformation possible in asset-intensive industries,” says John Markus Lervik, CEO and co-founder of Cognite. “It illustrates how to connect data from the IT and OT source to the data consumer with contextual tips that will empower organizations of all sizes to use it, innovate off of it, and reshape operations for efficiency, profitability, and sustainability. It is the strongest driver of change that will propel the industry forward, and this book will help companies as they navigate their way and capture immediate value at scale.”
“To make the promise of Industrial DataOps a reality for enterprises, ´The Definitive Guide to Industrial DataOps´ serves as a critical manual to not only understand this novel software category, but as well how it accelerates innovation and reduces time-to-value at each stage of a digital operations transformation,” says Pascal Brosset, Industry X Production & Operations Lead at Accenture.
The full book is available for download for free: The Definitive Guide To Industrial DataOps
About Cognite
Cognite is a global industrial SaaS company that was established with one clear vision: to rapidly empower industrial companies with contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-intensive industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion™, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter @CogniteData or LinkedIn: https://www.linkedin.com/company/cognitedata .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005582/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom